Arcadia Biosciences (RKDA) Liabilities and Shareholders Equity (2014 - 2026)

Arcadia Biosciences (RKDA) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $6.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 51.57% year-over-year to $6.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.9 million (down 42.25% YoY) and the FY2025 annual result came in at $6.5 million, down 51.57% from the prior year.
• Liabilities and Shareholders Equity declined to $6.5 million in Q4 2025, from $8.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $70.8 million in Q1 2021 to a low of $6.5 million in Q4 2025.
• A 5-year average of $29.0 million and a median of $25.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 119.55% — and 2025, when it slumped 55.16%.
• Tracing RKDA's Liabilities and Shareholders Equity over 5 years: stood at $43.9 million in 2021, then sank by 34.15% to $28.9 million in 2022, then tumbled by 31.87% to $19.7 million in 2023, then sank by 31.4% to $13.5 million in 2024, then sank by 51.57% to $6.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.5 million (Q4 2025), $8.6 million (Q3 2025), and $7.8 million (Q2 2025), per Business Quant data.